Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000687 · ClinicalTrials.gov registry record
Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss
A clinical trial of Type 1 Diabetes Mellitus, sponsored by Rodolfo Alejandro.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT02000687 is a study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by Rodolfo Alejandro. The registered enrollment target is 60 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02000687, a study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by Rodolfo Alejandro.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.
Conditions Studied
Study Locations (1)
Florida
- Diabetes Research Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-12 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000687
The ClinicalTrials.gov registry entry for NCT02000687 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (57% lower). The listed sponsor is Rodolfo Alejandro, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT02000687 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02000687 about?
NCT02000687 is a clinical study titled "Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss". This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.
What is the current status of trial NCT02000687?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2008-12. Estimated completion is 2028-07.
What conditions does trial NCT02000687 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
Who is sponsoring clinical trial NCT02000687?
This trial is sponsored by Rodolfo Alejandro, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02000687 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.